Hendriks J C, Satten G A, van Ameijden E J, van Druten H A, Coutinho R A, van Griensven G J
Department of Public Health, Municipal Health Service, Amsterdam, The Netherlands.
AIDS. 1998 Aug 20;12(12):1537-44. doi: 10.1097/00002030-199812000-00017.
To estimate the incubation-period distribution (time from seroconversion to AIDS) accounting for death before an AIDS diagnosis (DBAD) in a cohort of injecting drug users (IDU) in Amsterdam, The Netherlands and to compare these estimates with those previously obtained from a contemporaneous study of homosexual and bisexual men in Amsterdam carried out using the same facilities.
Participants in a cohort study begun in Amsterdam at the end of 1985 have scheduled follow-up visits every 4 months. All participants of Dutch nationality and who had two or more follow-up visits before January 1996 from which CD4 measurements were available were included in this study. Data concerning AIDS diagnosis and death were verified through review of national and municipal registries.
Because time of seroconversion was unknown for study participants and because IDU are at substantial risk for DBAD, we used a Markov model with CD4-based stages that allows for DBAD. The parameters in this model were estimated using the method of maximum likelihood and confidence intervals were calculated using bootstrap methods.
A total of 173 IDU (134 seroprevalent, 39 seroincident) made 1829 visits. Nearly 10% of the visits were non-consecutive. Forty-five IDU developed AIDS and 25 died without an AIDS diagnosis. We estimated that 24% [95% confidence interval (CI), 17-25%] of IDU die before an AIDS diagnosis. As a result, the median time from seroconversion to AIDS (10.5 years; 95% CI, 9.1-10.7 years) is considerably longer than the median time from seroconversion to death (8.3 years; 95% CI, 7.9-8.5 years). Conditional on survival to an AIDS diagnosis, the median time to AIDS is 8.2 years (95% CI, 7.7-8.7 years). The median survival time after a diagnosis of AIDS is estimated to be 1.0 years.
The high occurrence of DBAD in IDU has a considerable influence on estimates of the incubation-period distribution. Progression from seroconversion to death was faster in the IDU cohort than in a cohort of homosexual men in Amsterdam (median, 8.3 years and 9.6 years, respectively). However, progression to AIDS conditional on survival to an AIDS diagnosis seems to be similar in both the IDU cohort and in the cohort of homosexual men (median, 8.2 years and 8.3 years, respectively).
估计荷兰阿姆斯特丹一组注射吸毒者(IDU)从血清转化到艾滋病的潜伏期分布情况,同时考虑艾滋病诊断前死亡(DBAD)因素,并将这些估计值与之前在阿姆斯特丹使用相同设施对同性恋和双性恋男性进行的同期研究所得结果进行比较。
1985年末在阿姆斯特丹开始的一项队列研究中的参与者每4个月安排一次随访。本研究纳入了所有荷兰国籍且在1996年1月前有两次或更多次随访且可获得CD4测量值的参与者。通过查阅国家和市级登记处核实了有关艾滋病诊断和死亡的数据。
由于研究参与者的血清转化时间未知,且IDU有很高的DBAD风险,我们使用了一个基于CD4阶段的马尔可夫模型,该模型考虑了DBAD。使用最大似然法估计该模型中的参数,并使用自助法计算置信区间。
共有173名IDU(134名血清阳性,39名血清阴性)进行了1829次随访。近10%的随访是非连续的。45名IDU发展为艾滋病,25名在未确诊艾滋病的情况下死亡。我们估计24%[95%置信区间(CI),17 - 25%]的IDU在艾滋病诊断前死亡。因此,从血清转化到艾滋病的中位时间(10.5年;95%CI,9.1 - 10.7年)比从血清转化到死亡的中位时间(8.3年;95%CI,7.9 - 8.5年)长得多。在存活至艾滋病诊断的条件下,到艾滋病的中位时间为8.2年(95%CI,7.7 - 8.7年)。估计艾滋病诊断后的中位生存时间为1.0年。
IDU中DBAD的高发生率对潜伏期分布的估计有相当大的影响。IDU队列中从血清转化到死亡的进展比阿姆斯特丹同性恋男性队列更快(中位时间分别为8.3年和9.6年)。然而,在存活至艾滋病诊断的条件下,IDU队列和同性恋男性队列中发展为艾滋病的进展似乎相似(中位时间分别为8.2年和8.3年)。